ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00907205
Recruitment Status : Completed
First Posted : May 22, 2009
Last Update Posted : June 13, 2013
Sponsor:
Collaborator:
SignalRX Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Semafore Pharmaceuticals